Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

1. Front Matter

   Pages i-xiii

   PDF

2. Multidrug Resistance in Cancer: A Tale of ABC Drug Transporters

   • Khyati Kapoor, Hong May Sim, Suresh V. Ambudkar

   Pages 1-34

3. Multidrug Resistance: A Role for Membrane Physics, pH and Drug Transporters

   • Chloe Daniel, Cyril Rauch

   Pages 35-46

4. Mechanisms and Potential Therapies for Acquired Resistance to Inhibitors Targeting the Raf or MEK Kinases in Cancer

   • Alyson K. Freeman, Deborah K. Morrison

   Pages 47-67

5. Mechanisms of Resistance to Targeted B-Raf Therapies

   • Ramana V. Tantravahi, Benjamin Hoffman, E. Premkumar Reddy

   Pages 69-88

6. Role of β1 Integrins in the Complication and Drug Resistance Against Lung Cancer: Targeting β1 Integrins to Eradicate Lung Cancer

   • Srirupa Mukhopadhyay, Parth Malik, Sunil Kumar Arora, Tapan K. Mukherjee

   Pages 89-108

7. Aldo-Keto Reductases as New Therapeutic Targets for Colon Cancer Chemoresistance

   • Toshiyuki Matsunaga, Ossama El-Kabbani, Akira Hara

   Pages 109-133

8. Overcoming Drug Resistance Through Elevation of ROS in Cancer

   • Amit K. Maiti

   Pages 135-149

9. Cancer Stem Cells in Resistance to Cytotoxic Drugs: Implications in Chemotherapy

   • Man-Tzu Wang, Hongmei Jiang, Debasish Boral, Daotai Nie

   Pages 151-161

10. Two Birds with a Stone: Molecular Cancer Therapy Targeting Signal Transduction and DNA Repair Pathways

    • Elisa Zucca, Emmanuele Crespan, Federica Bertoletti, Miroslava Kissova, Giovanni Maga

    Pages 163-186

11. Collateral Sensitivity in Drug-Resistant Tumor Cells

    • Mohamed Saeed, Henry Johannes Greten, Thomas Efferth

    Pages 187-211

12. Human Cancer Resistance to Trail-Apoptotic Pathway-Targeted Therapies

    • Anita C. Bellail, Chunhai Hao

    Pages 213-243

13. The Dark Side of Apoptosis

    • Malathy P. V. Shekhar

    Pages 245-258

14. Erratum to: Overcoming Drug Resistance Through Elevation of ROS in Cancer

    • Amit K. Maiti

    Pages E1-E3

15. Back Matter

    Pages 259-260

    PDF

​​​​​This volume gives the latest developments in on the mechanisms of cancer cell resistance to apoptotic stimuli, which eventually result in cancer progression and metastasis. One of the main challenges in cancer research is to develop new therapies to combat resistant tumors. The development of new effective therapies will be dependent on delineating the biochemical, molecular, and genetic mechanisms that regulate tumor cell resistance to cytotoxic drug-induced apoptosis. These mechanisms should reveal gene products that directly regulate resistance in order to develop new drugs that target these resistance factors and such new drugs may either be selective or common to various cancers. If successful, new drugs may not be toxic and may be used effectively in combination with subtoxic conventional drugs to achieve synergy and to reverse tumor cell resistance. The research developments presented in this book can be translated to produce better clinical responses to resistant tumors.

• ABC Drug transporters
• HPC1
• apoptosis
• chemoresistance
• cytotoxics
• β1 Integrins
• antibacterial drug resistance

• Dept. Microbiology, Immunology &, Molecular Genetics, University of California, Los Angeles, Los Angeles, USA

  Benjamin Bonavida

Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.

Policies and ethics